Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03000452
Title A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)
Acronym FUSION-MM-005
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | SWE | NLD | GRC | ESP | AUT


No variant requirements are available.